Legal Regulations Governing Pharmaceuticals, Door-to-Door Sales, and Other Activities
First written in FY2016. 17 of 18 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2020: 1 of 9 companies on the "Worse" side.
10 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Because the Company engages in the placement sale of pharmaceuticals and related activities, it is subject to regulations under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices and other laws and requires the permits, registrations, and notifications of each prefecture shown in the table below. In addition, because its retail sales use a door-to-door sales system, they are subject to the Act on Specified Commercial Transactions.」
The Company continues to identify legal regulations and risks relating to permits and approvals under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, the Act on Specified Commercial Transactions, and other laws. - FY2025-H1RestatedAnnual report
「During the interim accounting period, no new business or other risks arose. In addition, there were no significant changes to the business and other risks described in the securities report for the previous fiscal year.」
No material changes are identified in the legal and regulatory risks relating to pharmaceuticals, door-to-door sales, and other activities. - FY2024-Q3RestatedAnnual report
「During the cumulative third-quarter period, no new business or other risks arose. In addition, there were no significant changes to the business and other risks described in the securities report for the previous fiscal year.」
No material changes are identified in the legal and regulatory risks relating to pharmaceuticals, door-to-door sales, and other activities. - FY2024-Q2RestatedAnnual report
「During the cumulative second-quarter period, no new business or other risks arose. In addition, there were no significant changes to the business and other risks described in the securities report for the previous fiscal year.」
No material changes are identified in the legal and regulatory risks relating to pharmaceuticals, door-to-door sales, and other activities. - FY2023-Q3RestatedAnnual report
「During the cumulative third-quarter period, no new business or other risks arose. In addition, there were no significant changes to the business and other risks described in the securities report for the previous fiscal year.」
No material changes are identified in the legal and regulatory risks relating to pharmaceuticals, door-to-door sales, and other activities. - FY2023-Q2RestatedAnnual report
「During the cumulative second-quarter period, no new business or other risks arose. In addition, there were no significant changes to the business and other risks described in the securities report for the previous fiscal year.」
No material changes are identified in the legal and regulatory risks relating to pharmaceuticals, door-to-door sales, and other activities. - FY2021-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter. There were also no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
No material changes are identified in the legal and regulatory risks relating to pharmaceuticals, door-to-door sales, and other activities. - FY2021-Q2RestatedAnnual report
「During the cumulative second-quarter period, no new business or other risks arose. In addition, there were no significant changes to the business and other risks described in the securities report for the previous fiscal year.」
No material changes are identified in the legal and regulatory risks relating to pharmaceuticals, door-to-door sales, and other activities. - FY2020-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter. There were also no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
No material changes are identified in the legal and regulatory risks relating to pharmaceuticals, door-to-door sales, and other activities. - FY2020-Q1RestatedAnnual report
「No new business or other risks arose during the cumulative first quarter. There were also no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
No material changes are identified in the legal and regulatory risks relating to pharmaceuticals, door-to-door sales, and other activities. - FY2019-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter. There were also no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
No material changes are identified in the legal and regulatory risks relating to pharmaceuticals, door-to-door sales, and other activities. - FY2018-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter. There were also no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
No material changes are identified in the legal and regulatory risks relating to pharmaceuticals, door-to-door sales, and other activities. - FY2018-Q1RestatedAnnual report
「No new business or other risks arose during the cumulative first quarter. There were also no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
No material changes are identified in the legal and regulatory risks relating to pharmaceuticals, door-to-door sales, and other activities. - FY2017RestatedAnnual report
「Because the Company engages in the placement sale of pharmaceuticals and related activities, it is subject to regulations under the Pharmaceutical Affairs Act and other laws and requires the permits, registrations, and notifications of each prefecture shown in the table below. In addition, because its retail sales use a door-to-door sales system, they are subject to the Act on Specified Commercial Transactions.」
The Company continues to identify permits and approvals, laws and regulations relating to pharmaceuticals and door-to-door sales, and the risks of regulatory changes and tightening as risks. - FY2017-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter. There were also no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
No material changes are identified in the legal and regulatory risks relating to pharmaceuticals, door-to-door sales, and other activities. - FY2017-Q2RestatedAnnual report
「No new business or other risks arose during the six-month period ended the second quarter. In addition, no material changes have occurred in the business and other risks described in the annual securities report for the previous fiscal year.」
No material changes are identified in the legal and regulatory risks relating to pharmaceuticals, door-to-door sales, and other activities. - FY2017-Q1RestatedAnnual report
「No new business or other risks arose during the cumulative first quarter. There were also no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
No material changes are identified in the legal and regulatory risks relating to pharmaceuticals, door-to-door sales, and other activities. - FY2016First statedAnnual report
「Because the Company engages in the placement sale of pharmaceuticals and related activities, it is subject to regulations under the Pharmaceutical Affairs Act and other laws and requires the permits, registrations, and notifications of each prefecture shown in the table below. In addition, because its retail sales use a door-to-door sales system, they are subject to the Act on Specified Commercial Transactions.」
Changes to or tightening of regulations, new regulations, and the inability to comply are identified as risks. The permits and registrations are shown as having a six-year validity period.